Validation data for Anti-hBCMA-CD3

https://www.invivogen.com/anti-hbcma-cd3

For research use only

Version 22G06-AK

Anti-hBCMA-CD3 is a bispecific antibody that binds to two sites: hCD3, part of the T cell receptor and hBCMA expressed on the surface of B cells, plasma cells and multiple myeloma cells. It features the variable regions of pacanalotamab, a bispecific antibody developed for the treatment of relapsed/refractory multiple myeloma. Anti-hBCMA-CD3 engages T-cell cytotoxicity upon connection of CD3 in the T cell receptor (TCR) complex with hBCMA on B cells. This causes T cells to proliferate and exert cytotoxic activity against tumor B cells. The ability of Anti-hBCMA-CD3 to activate T cells in the presence of B cells has been validated using InvivoGen's Jurkat-Lucia™ NFAT cells, a human T cell reporter cell line that stably expresses an NFAT-inducible Lucia luciferase reporter gene, and the human Raji B lymphoma cell line stably overexpressing hBCMA on their surface **(Figure 1)**. Since Raji-Null cells endogenously express hBMCA at a low level, a slight increase in Lucia expression was measured when the cells were treated with Anti-hBCMA-CD3.



Figure 1: Dose-dependent activation of Jurkat-Lucia™ NFAT cells with Anti-hBCMA-CD3 in the presence of Raji cells expressing hBCMA.
Raji BCMA or Raji Null cells were pre-incubated with increasing concentration of Anti-hBCMA-CD3 or Anti-hBCMA-IgG1 (negative control) for 30 minutes before addition of Jurkat-Lucia™ NFAT cells. After 24 hours incubation, T cell activation was determined by measuring the Lucia luciferase activity using QUANTI-Luc™ detection reagent. Results are presented as fold change over non-induced cells (mean ± SEM).

TECHNICAL SUPPORT
InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Asia: +852 3-622-3480
E-mail: info@invivogen.com